Anthi AK, Kolderup A, Vaage EB, Bern M, Benjakul S, Tjärnhage E, Ruso-Julve F, Jensen KR, Lode HE, Vaysburd M, Nilsen J, Herigstad ML, Sakya SA, Tietze L, Pilati D, Nyquist-Andersen M, Dürkoop M, Gjølberg TT, Peng L, Foss S, Moe MC, Low BE, Wiles MV, Nemazee D, Jahnsen FLet al.(2025) An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models Nat Commun, 16(1), 3999 DOI 10.1038/s41467-025-59353-6, PubMed 40312392
Olofsson A, Humbert M, Rekha RS, Frankling MH, Lund-Johansen F, Bergman P, Björkhem-Bergman L, Karlsson AC(2025) Adaptive immune responses against common viruses are sustained and functional in end-of-life patients iScience, 28(3), 112082 DOI 10.1016/j.isci.2025.112082, PubMed 40124502
Viermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, Bouscambert-Duchamp M, Assoumou L, Halvorsen B, Tekin NB, Diallo A, De Gastines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy Det al.(2024) Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial EBioMedicine, 111, 105511 DOI 10.1016/j.ebiom.2024.105511, PubMed 39731852
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no
